Cases & Deals

AnGes MG enters into collaborative agreement and invests $22.6 million in Vical

Clients AnGes MG, Inc.

Jones Day advised AnGes MG, Inc. in connection with its purchase of $22.6 million of Common Stock in a private placement by Vical Incorporated.

Vical and AnGes MG, Inc. also entered into a collaborative agreement for Vical's Allovectin-7® cancer immunotherapeutic. Under the agreement, AnGes will provide up to $100 million in ongoing clinical trial funding and future sales-based milestones as Allovectin-7® is successfully commercialized. Vical retains exclusive marketing rights for Allovectin-7® in the United States and the rest of the world outside of specified Asian countries, for which AnGes received exclusive rights.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.